Skip to main content
Industry News
FDA OKs AstraZeneca's combo diabetes drug

AstraZeneca's Qternmet XR, a combination therapy that contains dapagliflozin, metformin and saxagliptin, has been approved by the FDA as an adjunct to diet and exercise for patients with type 2 diabetes. The approval was based on the results of two Phase III trials, both of which showed significant HbA1C reductions among those given the drug.

Full Story: